Document Detail

Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure.
MedLine Citation:
PMID:  17032344     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Natriuretic peptides, particularly brain natriuretic peptide (BNP), are elevated in heart failure and therefore considered to be excellent predictors of outcome. Vasopressin is also known to be related to the severity of heart disease. Copeptin--an inactive fragment of the vasopressin precursor--has not been previously investigated in the context of heart failure. MATERIALS AND METHODS: We prospectively studied 268 patients with advanced heart failure after they had been discharged from the hospital. We investigated the ability of BNP and copeptin to predict death, re-hospitalization due to heart failure, and a combination of the two endpoints. RESULTS: Over a mean follow-up period of 15.8 months (up to 24 months), 83 patients died, 122 patients experienced worsening of heart failure, and 145 patients achieved the combined endpoint. Univariate predictors of death were copeptin, BNP, age and impaired kidney function. In multivariate analysis, copeptin (chi(2) = 16, P < 0.0001) and age (chi(2) = 4, P < 0.05) were independent predictors. Univariate predictors of re-hospitalization due to heart failure were copeptin, BNP, age and impaired kidney function. Furthermore, in multivariate analysis BNP (chi(2) = 18, P < 0.0001), age (chi(2) = 11.8, P < 0.001) and copeptin (chi(2) = 4.2, P < 0.05) were found to be independent predictors. CONCLUSION: Our study is the first to show that copeptin is an excellent predictor of outcome in advanced heart failure patients. Its value is superior to that of BNP in predicting death and a combined endpoint, although BNP is still suitable for predicting chronic heart failure (CHF) re-hospitalization. Our data imply that vasopressin antagonism might be a new target to improve outcome in this population.
B Stoiser; D Mörtl; M Hülsmann; R Berger; J Struck; N G Morgenthaler; A Bergmann; R Pacher
Related Documents :
18818124 - Changes in tissue-doppler echocardiographic assessment of left ventricular filling duri...
20191004 - Interpretation and use of natriuretic peptides in non-congestive heart failure settings.
17977844 - Growth-differentiation factor-15 improves risk stratification in st-segment elevation m...
16713594 - Evaluation of cardiac laboratory markers in patients with systemic sclerosis.
15227324 - Jean-baptiste sénac and his treatise on the heart.
17483244 - Effects of cardiopulmonary bypass surgery on coronary flow in children assessed with tr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical investigation     Volume:  36     ISSN:  0014-2972     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-10-11     Completed Date:  2007-05-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  771-8     Citation Subset:  IM    
Medical University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Markers / blood
Chronic Disease
Glycopeptides / blood*
Heart Failure / diagnosis*,  mortality,  physiopathology
Multivariate Analysis
Natriuretic Peptide, Brain / blood*
Predictive Value of Tests
Prospective Studies
Reg. No./Substance:
0/Biological Markers; 0/Glycopeptides; 0/copeptins; 114471-18-0/Natriuretic Peptide, Brain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients w...
Next Document:  Paraoxonase and arylesterase activities in coronary artery disease.